SARC038:vPhase 2 Study of Regorafenib and Nivolumab in Osteosarcoma (Appendix 9) Grant

Overview

date/time interval

July 1, 2021 - June 30, 2028

awarded by

Sarcoma Alliance for Research through Collaboration

administered by

Population Health Sciences

sponsor award ID

SARC 220743-01